Literature DB >> 9703776

Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer.

S Krämer1, R Schulz-Wendtland, K Hagedorn, W Bautz, N Lang.   

Abstract

Breast conserving therapy (BCT) has turned out to be the standard procedure for the treatment of breast cancer. While the risk of local recurrences was reported as 1-2% or more per year after treatment, follow-up including clinical examination, mammography and even sonography is of priority. This study was performed to assess the efficacy of contrast-enhanced dynamic magnetic resonance tomography (NMR) for the diagnosis of local recurrences after breast conserving therapy, compared to palpation, mammography and ultrasound. In 33 patients local recurrences within the breast were diagnosed after breast conserving surgery. The sensitivity for the diagnosis of local recurrences after BCT was as follows: palpation (51%), mammography (67%), ultrasound (85%) and NMR (91%). All multicentric local recurrences were diagnosed by NMR. Mammography was not able to diagnose 11 local recurrences in radiodense breasts. Here ultrasound was able to diagnose 8 of 11 recurrences, while NMR was able to diagnose 10 of 11 recurrences. Therefore, ultrasound should be included into routine follow-up protocols after BCT to achieve an acceptable sensitivity for the detection of local recurrences. Under defined conditions and indications MRI is the best method to complement mammography and sonography with the highest sensitivity for the diagnosis of local recurrences in the radiodense breast.

Entities:  

Mesh:

Year:  1998        PMID: 9703776

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  [Suspected contrast medium concentration in dynamic MR-mammography. Post-traumatic fracture of the ribs].

Authors:  A Fink; K Wasser; D Aufderstrasse; H Ludemann; S Delorme
Journal:  Radiologe       Date:  2002-09       Impact factor: 0.635

Review 2.  Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis.

Authors:  Cameron B Haas; Larissa Nekhlyudov; Janie M Lee; Sara H Javid; Mary Bush; Dianne Johnson; Timothy Gleason; Cary Kaufman; Jennifer Specht; Sean Stitham; Karen J Wernli
Journal:  Breast Cancer Res Treat       Date:  2020-04-17       Impact factor: 4.872

3.  Follow-up of women with breast cancer: comparison between MRI and FDG PET.

Authors:  Gerhard W Goerres; Sven C A Michel; Mathias K Fehr; Achim H Kaim; Hans C Steinert; Burkhardt Seifert; Gustav K von Schulthess; Rahel A Kubik-Huch
Journal:  Eur Radiol       Date:  2002-11-13       Impact factor: 5.315

4.  Intraoperative Supine Breast MR Imaging to Quantify Tumor Deformation and Detection of Residual Breast Cancer: Preliminary Results.

Authors:  Eva C Gombos; Jagadeesan Jayender; Danielle M Richman; Diana L Caragacianu; Melissa A Mallory; Ferenc A Jolesz; Mehra Golshan
Journal:  Radiology       Date:  2016-06-22       Impact factor: 11.105

5.  Magnetic resonance mammography in the evaluation of recurrence at the prior lumpectomy site after conservative surgery and radiotherapy.

Authors:  Lorenzo Preda; Gaetano Villa; Stefania Rizzo; Luca Bazzi; Daniela Origgi; Enrico Cassano; Massimo Bellomi
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

6.  Clinicopathologic and prognostic features of breast cancer in young women: a series from North of Morocco.

Authors:  Joaira Bakkach; Mohamed Mansouri; Touria Derkaoui; Ali Loudiyi; Mohamed Fihri; Samia Hassani; Amina Barakat; Naima Ghailani Nourouti; Mohcine Bennani Mechita
Journal:  BMC Womens Health       Date:  2017-11-09       Impact factor: 2.809

7.  Breast MRI: guidelines from the European Society of Breast Imaging.

Authors:  R M Mann; C K Kuhl; K Kinkel; C Boetes
Journal:  Eur Radiol       Date:  2008-04-04       Impact factor: 5.315

Review 8.  Current applications and future direction of MR mammography.

Authors:  P J Kneeshaw; L W Turnbull; P J Drew
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.